BIOTECHNOLOGY company Evinco Therapeutics has launched in Melbourne, with the aim of setting new benchmarks for innovation and patient outcomes in the rapidly evolving field of treatment for neurodegenerative diseases.
Evinco will conduct research into novel treatments for Alzheimer's Disease and other neurological conditions featuring intranasal delivery to transport therapeutics directly into the affected area of the brain.
Operating under the leadership of Prof Alan Trounson, Evinco is a spin-out from Cartherics, which will now focus on cancer and endometriosis therapies.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Dec 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Dec 25
